Navigation Links
MedAvante Closes $20 Million Financing by Goldman Sachs, Trevi Health Ventures
Date:7/1/2008

Pioneer in Centralized Psychiatric Patient Evaluation for Clinical Trials

Expanding Into New Areas of Drug Development

HAMILTON, N.J., July 1 /PRNewswire/ -- MedAvante, Inc., the leader in centralized psychiatric patient evaluation, announced today that it has closed a $20 million financing by Goldman, Sachs & Co. and Trevi Health Ventures. MedAvante has developed an innovative platform to centralize and calibrate the assessment of patients undergoing treatment in clinical trials in order to more reliably and precisely measure their response to therapies. MedAvante currently provides centralized patient evaluation services to many of the world's largest pharmaceutical companies with central nervous system drug candidates, and has administered more than 21,000 remote expert assessments for Phase 2 and Phase 3 large pharma studies including acute schizophrenia, major depressive disorder, generalized anxiety disorder, and psychotic depression.

The Company will use the capital to fund the expansion of its existing patient evaluation platform to meet increasing demand from pharmaceutical companies. The capital will also enable MedAvante to apply its platform into new areas of drug development, including monitoring by mental health professionals of potential warning signs for suicide. The U.S. Food and Drug Administration (FDA) is requiring most drugs with centrally acting mechanisms to be assessed for suicidality, regardless of whether the drugs are being developed for neurological or psychiatric indications.

"The investment by Goldman Sachs and Trevi Health gives MedAvante the capital and resources to deliver on our mission of helping the life sciences industry bring better and safer drugs to patients faster," stated Paul Gilbert, Chief Executive Officer of MedAvante. Gilbert further noted, "Our unique ability to centralize and standardize the assessment of psychiatric patient's disease severity and progression is transforming
'/>"/>

SOURCE MedAvante, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Florida , September 19, 2014 ... release latest developments, patents and results of studies and ... Eli Lilly and Company (NYSE: LLY ), ... Corporation (NASDAQ: CELG ) and Arena Pharmaceuticals ... a leader in developing prodrug therapeutics for the treatment ...
(Date:9/19/2014)... The new , Healthcare and Life Sciences Review ... PharmaBoardroom.com for free download , looks beyond ... economy in 2009, and the austerity measures that followed, to ... times of trouble. "Despite the crisis, ... and the general conditions to invest are favorable to the ...
(Date:9/18/2014)... A novel robotic system that can operate inside ... tested as part of a biomedical research partnership program ... aim of determining if the robot, in conjunction with ... more accurate, less costly, and less discomforting for the ... deliver prostate cancer therapies with greater precision. , Developed ...
(Date:9/18/2014)... Research and Markets has announced ... Cell Industry Report, 2014-2017" report to their offering. ... that can differentiate into specialized cells and can divide ... therapy can be applied to treatment of cardiovascular diseases, ... diseases, damage or lesion of liver, kidney and other ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3
... 28 Stryker Corporation (NYSE: SYK ) ... of the Neurovascular division of Boston Scientific in an ... million of milestone payments. The purchase price also reflects ... benefit for Stryker based on the asset purchase structure ...
... Beckman Coulter, Inc. (NYSE: BEC ... products that simplify, automate, and innovate complex biomedical ... senior vice president and chief financial officer will ... on Wednesday, November 3, 2010 at 2:45p ET. ...
... SRI International, an independent nonprofit research and development ... joined SRI International,s Center for Advanced Drug Research (CADRE) ... Geysen will expand SRI,s research capabilities into diseases such ... develop novel molecules that control hormonal regulation in metabolic ...
Cached Biology Technology:Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion 2Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion 3Stryker Announces Definitive Agreement to Acquire the Neurovascular Division of Boston Scientific for $1.5 Billion 4Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs 2Distinguished Scientist H. Mario Geysen Joins SRI International to Lead Combinatorial Sciences and Metabolic Diseases Research Programs 3
(Date:9/18/2014)... tonight at the third annual Golden Goose Award ceremony ... infants and in paving the way for the telecommunications ... by the National Science Foundation, the National Institutes of ... honored at a ceremony at the Library of Congress ... Congress will be on hand to help present their ...
(Date:9/18/2014)... September 18, 2014 Elsevier, a world-leading provider ... services, and the Australasian Research Management Society (ARMS), ... scientists at the 5th Scopus Young Researcher of ... earlier today at the National Convention Centre and ... was attended by guests representing Australia,s and New ...
(Date:9/18/2014)... probably the ultimate form of camouflage: you don,t just ... strategy is not as uncommon as you might think. ... USA, explains that the larval life stages of many ... of the anatomy that most creatures cannot make transparent. ... to shield each individual eye unit with an opaque ...
Breaking Biology News(10 mins):3rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Transparent larvae hide opaque eyes behind reflections 2
... mussels and a polymer that repels cells and ... versatile new two-sided coating that could breathe life ... certain medical implants suffers because bacteria, cells and ... devices (known as fouling), compromising their performance and ...
... already known to control cell movement are also needed ... the April issue of Developmental Cell. , The researchers ... dividing cell's halves to separate, raising the possibility that ... uncontrolled cell division found in cancers. Mutations in the ...
... We have much to learn from bad bugs, according to ... Can Teach Us" was published March 1 (Prometheus Books). , ... is spent on their research," said Waldbauer, professor emeritus of ... 900,000 known species of insects, a mere 2 percent are ...
Cached Biology News:Innovative coating could give medical implants a longer life 2Pair of cancer genes found to drive both cell migration and division 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 2Bugs, even 'bad' ones, can be educationally beneficial, new book says 3
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
Mouse monoclonal antibody to DCAMKL2 - doublecortin and CaM kinase-like 2...
... IKATUBE ULTRA TURRAX Tube Disperser System from IKA ... It offers a cleaner, safer, and more efficient ... sample volumes from 2 to 15 ml inside ... can choose one of 4 different tube types. ...
... member of Wyatt Technology's family of light ... your high temperature chromatograph and enables you ... thermoplastic polymers. The HTmD is easily installed ... PL220C or Alliance 2000 device and enables ...
Biology Products: